AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read$OPK

OPKO Health to Sell BioReference Lab Assets to Labcorp for $722 Million Plus Earnout

OPKO Health (OPK) agreed to sell BioReference's lab testing assets to Labcorp for $722M upfront, plus potential $150M earnout over 10 years. The deal, not contingent on financing, is subject to regulatory approval and may include a $28.88M termination fee if terminated for antitrust reasons. Closing is expected by Oct 14, 2026.

Original reporting
tradingview.com
Published Oct 15, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OPKO Health to Sell BioReference Lab Assets to Labcorp for $722 Million Plus Earnout — source image
Source · tradingview.com
Decision brief

The 30-second read

$OPKBullishHigh
01

Why it matters

The transaction reshapes OPKO's portfolio and expands Labcorp's testing capabilities.

02

Market read

First‑report M&A deal with >$700M cash component; likely moves both stocks on announcement.

03

What to watch

Regulatory HSR clearance risk and potential termination fee could affect deal timing.

Relevance 9/10Novelty 9/10Timing: immediate reaction expected today

Background

OPKO Health is a diversified biopharma company; Labcorp is a leading clinical laboratory services provider.

Company-level read

Ticker impact

$OPKBullishHigh confidence
Context

OPKO Health disclosed a $722M cash sale of BioReference lab assets to Labcorp, plus a potential $150M earnout.

Expected impact

likely upside as market prices in the cash proceeds and reduced operating exposure

Evidence & confidence

The deal provides immediate liquidity and removes a non‑core business, which traders typically view favorably.

Market effects

Sector

Consolidation in the clinical pathology market may pressure peers.

Regional

U.S. healthcare sector sees modest re‑pricing.

Global

Limited to U.S. lab services industry.

Counterpoint

What could challenge this read

If the earnout underperforms, Labcorp could face unexpected costs, turning the deal negative.

Key entities

  • Company
    OPKO Health

    Seller of BioReference lab assets.

  • Company
    Labcorp

    Buyer acquiring the assets.

Read at source← All news

StoryLabcorp to acquire OPKO’s BioReference assets for up to $872 million

Also covered by

6 outlets

Related articles

OCT 15
$LHHighAI 9/10

Labcorp Slides As Costly OPKO Deal Jolts Investors

Labcorp (LH) shares fell after announcing an $872M deal to acquire BioReference Health assets from OPKO, with up to $150M tied to the 4Kscore prostate cancer test's revenue. Investors are concerned about integration risks and cash outlay, though long-term growth prospects remain. Medicare reimbursement cuts and debt levels are additional risks.

tipranks.com2 min
OCT 15
$LHHighAI 9/10

Labcorp to Acquire BioReference Assets From OPKO for $872M

Labcorp agreed to acquire OPKO Health's remaining BioReference Health assets for up to $872M, including clinical diagnostics and the 4Kscore prostate cancer test. OPKO shares rose 20% premarket. The deal follows prior acquisitions of BioReference units, allowing OPKO to focus on biopharmaceuticals. Labcorp expects the acquired businesses to generate $250M in annual revenue.

hoodline.com3 min
OCT 15
$LHHighAI 9/10

Labcorp outlays up to $872m to acquire BioReference’s laboratory assets

Labcorp is acquiring laboratory assets from BioReference Health, an OPKO Health subsidiary, for up to $872m. The deal includes BioReference's clinical and women's health testing services, urology, corrections, and the 4Kscore prostate cancer test. Labcorp will pay $722m upfront, with up to $150m in potential earnouts. The transaction aims to expand Labcorp's diagnostic services and streamline OPKO's operations.

finance.yahoo.com2 min
OCT 15
$LHHighAI 9/10

Labcorp to buy BioReference assets for up to $872M

Labcorp will acquire laboratory testing assets from BioReference Health, an Opko Health subsidiary, for $722M, with up to $150M more contingent on prostate cancer test revenue. The total price may vary based on closing revenues, according to the companies.

finance.yahoo.com1 min
OCT 15
$OPKHighAI 9/10

OPKO Health Stock Jumps 16% On BioReference Asset Sale To Labcorp

OPKO Health (OPK) rose 16.13% to $1.5910 after agreeing to sell BioReference Health assets to Labcorp for $722M, with up to $150M in earnouts. The deal includes clinical testing businesses and the 4Kscore Test. Trading volume surged to 30.99M shares. OPK shares have ranged from $0.98 to $1.75 over the past year.

rttnews.com3 min